Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm

被引：41

作者：

Banna, Giuseppe Luigi ^{[1
]}

Cantale, Ornella ^{[1
]}

Bersanelli, Melissa ^{[2
]}

Del Re, Marzia ^{[3
]}

Friedlaender, Alex ^{[4
]}

Cortellini, Alessio ^{[5
]}

Addeo, Alfredo ^{[4
]}

机构：

[1] Portsmouth Hosp NHS Trust, Deparment Med Oncol, Portsmouth, Hants, England

[2] Univ Parma, Med & Surg Dept, Med Oncol Unit, Parma, Italy

[3] Univ Pisa, Dept Clin & Expt Med, Unit Clin Pharmacol & Pharmacogenet, Pisa, Italy

[4] Geneva Univ Hosp, Oncol Dept, Geneva, Switzerland

[5] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Med Oncol Unit, St Salvatore Hosp, Laquila, Italy

来源：

ONCOLOGY REVIEWS | 2020年 / 14卷 / 02期

关键词：

Immune-checkpoint inhibitor; PD1; PD-L1; lung cancer; immune-related adverse events; IMMUNE-CHECKPOINT INHIBITORS; ACQUIRED-RESISTANCE; SQUAMOUS-CELL; SOLID TUMORS; OPEN-LABEL; DOCETAXEL; NIVOLUMAB; PD-1; PEMBROLIZUMAB; CHEMOTHERAPY;

D O I：

10.4081/oncol.2020.490

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Anti-PD1 and anti-PD-L1 agents may have intrinsic and clinically relevant differences in the treatment of non-small cell lung cancer (NSCLC) patients. By reviewing currently available indirect evidence on these agents for NSCLC treatment, highlighting possible inter- and intra-class dissimilarities, anti-PD1 agents showed a higher response rate and a better outcome when combined with chemotherapy for the first-line treatment of patients with squamous and PD-L1 low advanced NSCLC, as compared to anti-PD-L1 agents. Conversely, anti-PD-L1 agents were responsible for less severe adverse events (AEs), particularly, immune-related AEs. These differences could be explained by their different specific properties. Considering possible differences between anti-PD1 and anti-PD-L1 agents could be clinically relevant for treatment tailoring and inspiring new investigational approaches.

引用

页码：135 / 143

页数：9

共 56 条

[1] Tumor Mutation Burden-From Hopes to Doubts [J].

Addeo, Alfredo ;

Banna, Giuseppe L. ;

Weiss, Glen J. .

JAMA ONCOLOGY, 2019, 5 (07) :934-935

[2] Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis [J].

Addeo, Alfredo ;

Banna, Giuseppe Luigi ;

Metro, Giulio ;

Di Maio, Massimo .

FRONTIERS IN ONCOLOGY, 2019, 9

[3]

[Anonymous], 2018, J CLIN ONCOL

[4]

[Anonymous], 2018, J CLIN ONCOL S

[5] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[6] Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection [J].

Banna, Giuseppe Luigi ;

Passiglia, Francesco ;

Colonese, Francesca ;

Canova, Stefania ;

Menis, Jessica ;

Addeo, Alfredo ;

Russo, Antonio ;

Cortinovis, Diego Luigi .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 129 :27-39

[7] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[8] Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population [J].

Brzezianska, Ewa ;

Karbownik, Malgorzata ;

Migdalska-Sek, Monika ;

Pastuszak-Lewandoska, Dorota ;

Wloch, Jan ;

Lewinski, Andrzej .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 599 (1-2) :26-35

[9] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].

Carbone, D. P. ;

Reck, M. ;

Paz-Ares, L. ;

Creelan, B. ;

Horn, L. ;

Steins, M. ;

Felip, E. ;

van den Heuvel, M. M. ;

Ciuleanu, T. -E. ;

Badin, F. ;

Ready, N. ;

Hiltermann, T. J. N. ;

Nair, S. ;

Juergens, R. ;

Peters, S. ;

Minenza, E. ;

Wrangle, J. M. ;

Rodriguez-Abreu, D. ;

Borghaei, H. ;

Blumenschein, G. R. ;

Villaruz, L. C. ;

Havel, L. ;

Krejci, J. ;

Corral Jaime, J. ;

Chang, H. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Chen, A. C. ;

Socinski, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426

[10] FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy [J].

Chen, Xin ;

Song, Xiaomin ;

Li, Kang ;

Zhang, Tong .

FRONTIERS IN IMMUNOLOGY, 2019, 10

← 1 2 3 4 5 6 →